Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 19, Status: Authorised

PSUSA/00010856/202408

Human medicines European public assessment report (EPAR): Akynzeo, netupitant,palonosetron, Date of authorisation: 27/05/2015, Revision: 19, Status: Authorised

QRD veterinary Appendix I - Adverse event (PhV) MSs reporting details

Human medicines European public assessment report (EPAR): Avonex, interferon beta-1a, Date of authorisation: 13/03/1997, Revision: 39, Status: Authorised

Human medicines European public assessment report (EPAR): Ebglyss, Lebrikizumab, Date of authorisation: 16/11/2023, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Darzalex, daratumumab, Date of authorisation: 20/05/2016, Revision: 24, Status: Authorised

3Rs Working Party (3RsWP) plenary meeting - Public session on the 2025-2027 work plan, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 April 2025, 09:30 (CEST) to 2 April 2025, 10:30 (CEST)

Innovation Task Force (ITF) briefing meeting request form

Zirabev